A phase I trial of Rhenium (186Re) obisbemeda for Brain cancer in children, infants, neonates

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 21 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

15 May 2024 According to a Plus Therapeutics media release, company received notice of award for a $3 million grant from the United States Department of Defense, subject to customary documentation and approvals, to fund Phase 1 trial of rhenium (186Re) obisbemeda in children with high-grade glioma and ependymoma.
24 Apr 2024 New trial record
22 Apr 2024 According to a Plus Therapeutics media release, company today announced it has been selected for funding by the Department of Defense (DoD) office of the Congressionally Directed Medical Research Programs (CDMRP). Funding for pediatric brain cancer treatment is expected to begin in Q3 2024, pending contract finalization. It is expected to begin enrollment in the second half of 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com